These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 35741080)

  • 1. The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.
    Takahashi H; Yoshimatsu G; Faustman DL
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
    Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2: A Novel Target for Cancer Immunotherapy.
    Vanamee ÉS; Faustman DL
    Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
    Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
    Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
    Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.
    Quazi S
    Med Oncol; 2022 Sep; 39(12):215. PubMed ID: 36175687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFR2 pathways are fully active in cancer regulatory T cells.
    Okuzono Y; Muraki Y; Sato S
    Biosci Biotechnol Biochem; 2022 Feb; 86(3):351-361. PubMed ID: 35015831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
    Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
    Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
    Liao P; Jiang M; Islam MS; Wang Y; Chen X
    Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting TNFR2 in Cancer: All Roads Lead to Rome.
    Bai J; Ding B; Li H
    Front Immunol; 2022; 13():844931. PubMed ID: 35251045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant frequency of TNFR2-expressing CD4+ FoxP3+ regulatory T cells in nasopharyngeal carcinoma patients.
    Engku Abd Rahman ENS; Irekeola AA; Shueb RH; Mat Lazim N; Mohamud R; Chen X; Ghazali L; Awang NMSH; Haron A; Chan YY
    Cytokine; 2023 Oct; 170():156341. PubMed ID: 37657236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
    Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
    Front Immunol; 2018; 9():1274. PubMed ID: 29922294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4
    He T; Zhao Y; Zhao P; Zhao L; Zakaria J; Wang K
    Int Immunopharmacol; 2022 Jul; 108():108823. PubMed ID: 35623290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.